AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01845272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 32mg, amlodipine 10mg
Description: Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
Study NCT01318551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: single dose, 20 mg
Study NCT01318551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: single dose, 40 mg (optional)
Study NCT01318551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: single dose, 80 mg (optional)
Study NCT02464553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periradicular therapy (PRT)
Description: RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
Study NCT02259972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113823 solution
Study NCT02259972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113823 tablet
Study NCT02259972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02259972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat, high calorie breakfast
Description: only for dose group 5
Study NCT01055795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, Everolimus and LBH589
Description: Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~1. 3-6, All study drugs administered per dose level~2. 3-6, All study drugs administered per dose level~3. 3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B \& C; 30, Recommended Phase II Dose for all three compounds
Study NCT01038960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 3 months supervised interval training
Study NCT05954650 — intervention group
Intervention type: BEHAVIORAL
Intervention: Rehabilitation
Description: Physical therapy and multisensory stimulation adjusted to the needs of each patient.
Study NCT01469351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.~Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.~Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.~1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used.
Study NCT01469351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non-active study drug
Description: placebo
Study NCT03808311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment strategy regarding different systolic BP goals
Description: The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (\<120 mmHg in the intensive arm and \<140 mmHg in the standard arm).
Study NCT03808311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment strategy regarding different systolic BP goals
Description: The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (\<120 mmHg in the intensive arm and \<140 mmHg in the standard arm).
Study NCT00027053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: 50 to 150 mg qhs
Study NCT00027053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00574899 — intervention group
Intervention type: OTHER
Intervention: Questioners, blood specimens, prostate tissue specimens
Description: You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat.
Study NCT02619513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
Study NCT03686007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive MSM intervention handbook
Study NCT03686007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive MSM intervention research nurse coaching
Study NCT03686007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive ASCO print materials
Study NCT03686007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive CRA assistance
Study NCT03686007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: View the MSM intervention videos
Study NCT03686007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Media Intervention
Description: View ASCO Cancer.net videos
Study NCT03686007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03686007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04521764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein
Description: Given IT
Study NCT04521764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04521764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04521764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT04521764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02619513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Group GE\\GT\\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
Study NCT03904147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriClipTM Device
Description: Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
Study NCT03904147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TriClipTM Device
Description: Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
Study NCT03191058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy
Description: MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
Study NCT03191058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy
Description: In the ECT arm treatment, the MECTA spectrum 5000Q or the MECTA Sigma devices will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
Study NCT03184389 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prompt to use smartphone apps for stress management
Description: Study smartphone and software will be used to deliver intervention prompts to use stress management applications on the study smartphone at various times throughout the day, during at least 10 days of study participation. The delivery of prompts will be micro randomized to occur when participants are classified as stressed, and when participants are not classified as stressed. Headspace, a commercial stress management application, will be installed on the study smartphones. Thought Shakeup and Mood Surfing, stress management applications that are not commercially available, also will be installed on the study smartphones. These smartphone applications guide participants through stress management exercises that draw upon techniques from mindfulness, cognitive behavioral therapy, and acceptance and commitment therapy.
Study NCT03351244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: 28 week treatment period
Study NCT03351244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 28 week treatment period
Study NCT02200224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Testing
Study NCT02619513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindray M7 series
Description: Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
Study NCT02189447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous Photorefractive Keratectomy and Collagen Cross-linking in patients with keratoconus
Description: Photorefractive Keratectomy followed by Collagen Cross-linking in patients with keratoconus in the same surgical setting
Study NCT02474706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Study NCT02474706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipenem
Study NCT03300336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRIDE
Description: Implementation of STRIDE inpatient hospital mobility program
Study NCT03097315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg CLS-TA Suprachoriodal Injection
Description: CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints
Study NCT04601285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)
Description: Dose escalation period: JS108 is administered intravenously every three weeks (Q3W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: JS108 is administered intravenously Q3W at the corresponding dose.~Clinical expansion period: JS108 is administered intravenously Q3W at the recommended dose.
Study NCT03890939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP AutoSV Advanced System One
Description: A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
Study NCT03890939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dreamstation BiPaP AutoSV
Description: A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
Study NCT03890939 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ResMed S7 VPAP Adapt Device
Description: A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
Study NCT02306161 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SBRT
Study NCT02306161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Surgical Procedure
Description: Undergo surgery
Study NCT02306161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT02306161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03436290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention
Description: These patients will receive the palliative care intervention.
Study NCT04007562 — intervention group
Intervention type: DRUG
Intervention: Hydroxychloroquine Sulfate
Description: The dosage and the route of administration of Hydroxychloroquine Sulfate was the same than in Lupus disease:~Oral administration: administered in soluble form in patients under the age of 6 years old and administered in tablets in patients other the age of 6 years old with Lipin-1 deficiency.~The soluble form was prepared at the Necker Hospital Pharmacy. Dose: 6.5 mg/kg/day (max 400 mg/day). The plasma concentration of the drug during follow-up was made, in order to follow a possible overdose.
Study NCT03486730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT1718
Description: Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. This stage will have 3 to 6 patient cohorts until the recommended dose is established. The expansion phase will consist of two or more expansion cohorts to include tumour types known to commonly over-express MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment. A squamous NSCLC and basket cohort will include approximately 16 patients each with high MT1-MMP levels. In the expansion cohorts BT1718 will be administered intravenously at the once weekly RP2D established in Phase I, Stage 2.
Study NCT04960358 — intervention group
Intervention type: PROCEDURE
Intervention: Surface Electromyography
Description: will be applied Surface Electromyography to assess Flexion Relaxation Response
Study NCT03084419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: The IV dose varies according to weight:~\<60kg=500mg~≥60 but≤100kg=750mg >100kg=1g~This equates to approximately 10mg/kg.
Study NCT01013727 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging
Study NCT01013727 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging
Study NCT03884075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide injection once weekly
Study NCT01870466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: cilostazol bid for 7 days
Study NCT01870466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin qd for 7 days
Study NCT01870466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: rosuvastatin qd for 7 days
Study NCT02288637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olyset Plus LLIN
Description: Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use
Study NCT02288637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Olyset LLIN
Description: Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
Study NCT02288637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IRS
Description: Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
Study NCT04033289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip protection orthosis
Description: Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
Study NCT01747902 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biceps Tenotomy
Description: The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
Study NCT01747902 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biceps Tenodesis
Description: The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
Study NCT01320254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Gemcitabine, Panitumumab
Description: Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1
Study NCT01320254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin, Gemcitabine
Description: Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8
Study NCT01039207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01039207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Given IV
Study NCT02153827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Shoulder External Rotator Training
Description: Eccentric training exercise for the external rotators, 3 sets of 15 daily.
Study NCT02153827 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: General Shoulder exercise
Description: general exercise consisting of active shoulder movements
Study NCT00748930 — intervention group
Intervention type: OTHER
Intervention: Retrospective Chart Review and Data collection
Description: Retrospective Chart Review and Data collection
Study NCT03873688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expiratory muscle training
Description: The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.
Study NCT03873688 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: expiratory muscle training
Description: The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.
Study NCT00299221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: tacrolimus
Study NCT00299221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination therapy
Description: MMF
Study NCT03637829 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Water
Study NCT03637829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White chocolate
Description: Experimental snack treatment
Study NCT03637829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark chocolate 1
Description: Experimental snack treatment
Study NCT03637829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark chocolate 2
Description: Experimental snack treatment
Study NCT02944266 — intervention group
Intervention type: OTHER
Intervention: Pre operative Focus assessed Transthoracic echocardiographic assessment.
Study NCT03091335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music-listening
Description: Patients listen to music on headphones
Study NCT01972490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avastin
Description: Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (5mg/kg) followed by chemotherapy of mFOLFOX6 until progressive disease or unacceptable toxicity.